Safety Evaluation of SH003 and Docetaxel Combination in Patients With Breast and Lung Cancer: A Multi-Center, Open-Label, Dose Escalation Phase I Clinical Trial
The combination of SH003 and docetaxel demonstrated a favorable safety profile, with 4800 mg/day identified as maximum tolerated dose for SH003. These findings support further investigation in Phase II trials to assess therapeutic efficacy.<b>Trial Registration:</b> Clinical Research Information Service (https://cris.nih.go.kr) KCT0004770.
Authors
- Kyong Hwa Park (ORCID: https://orcid.org/0000-0002-2464-7920)
- Chunhoo Cheon (ORCID: https://orcid.org/0000-0002-7078-0079)
- Seok Yun Kang (ORCID: https://orcid.org/0000-0002-4995-9912)
- H Kim
- Seong‐Gyu Ko (ORCID: https://orcid.org/0000-0002-2345-430X)
- Sung Yong Lee (ORCID: https://orcid.org/0000-0002-8693-5792)
Institutions
- Korea University Medical Center (KR)
- Kyung Hee University (KR)
- Korea University (JP)
- Ajou University (KR)
Publication Details
- Journal
- Integrative Cancer Therapies
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/15347354251363892
- Citations
- 2
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Research Foundation of Korea